PET diagnosis of metastatic DTC using Cu-64 DOTA-TATE
| Project/Area Number |
15K09945
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
HIGUCHI TETSUYA 群馬大学, 大学院医学系研究科, 准教授 (60323367)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
YAMAGUCHI AIKO 群馬大学, 大学院医学系研究科, 寄付講座教員 (80609032)
|
|---|
| Research Collaborator |
IIDA YASUHIKO 鈴鹿医療科学大学, 薬学部, 教授 (60252425)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 甲状腺分化癌 / I-131治療抵抗性 / Cu-64 DOTA-TATE / Y-90 DOTA-TATE / FDG-PET / サイログロブリン倍加時間 / Cu-64 / DOTA-TATE / 分化型甲状腺癌 / ソマトスタチン受容体 / ヨード治療抵抗性 / 甲状腺癌 / RI治療 / PET |
|---|
| Outline of Final Research Achievements |
Clinical usefulness of FDG-PET and thyroglobulin (Tg) measurement for the early diagnosis of Radioactive Iodine Refractory Differentiated Thyroid Carcinoma (RR-DTC), was evaluated in patients treated with I-131. SUVmax value and shortened Tg doubling time (Tg-DT) calculated from recent 4 Tg values less than 1 year were suggested to be a useful predictor of progressive disease (PD).
On the other hand, nude mice inoculated with follicular thyroid cancer cell line (FTC-133) were injected by Cu-64 DOTA-TATE and In-111 DOTA-TATE and clear tumor accumulation were proved, thus experimental Sstr-2 expressing animal model was established. Y-90 DOTA-TATE was used and treatment experiment was performed in 3 groups: control (n=5), 200 μCi (n=4) and 300 μCi (n=4). Dose dependent therapeutic effect was confirmed with the best response in 300 μCi group.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
[Journal Article] Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.2018
Author(s)
Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T
-
Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Volume: 45
Issue: 1
Pages: 56-66
DOI
Related Report
Peer Reviewed
-
-
-
-
-
[Journal Article] Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma2016
Author(s)
Okano Y, Satoh T, Horiguchi K, Toyoda M, Osaki A, Matsumoto S, Tomaru T, Nakajima Y, Ishii S, Ozawa A, Shibusawa N, Shimada T, Higuchi T, Chikamatsu K, Yamada M
-
Journal Title
Endocrine Journal
Volume: 63
Issue: 10
Pages: 905-912
DOI
NAID
ISSN
0918-8959, 1348-4540
Related Report
Peer Reviewed / Open Access
-
-
-
-
[Journal Article] Differentiation of malignant tumours from granulomas by using dynamic [(18)F]-fluoro-L-α-methyltyrosine positron emission tomography.2015
Author(s)
Yamaguchi A, Hanaoka H, Fujisawa Y, Zhao S, Suzue K, Morita A, Tominaga H, Higuchi T, Hisaeda H, Tsushima Y, Kuge Y, Iida Y.
-
Journal Title
EJNMMI Res.
Volume: 5
Issue: 1
Pages: 29-29
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
